Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. (6r)-6-(2-(ethyl((4-(2-(ethylamino)ethyl)phenyl)methyl)amino)-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol
1. 722533-56-4
2. Rad1901
3. Elacestrant [inn]
4. Elacestrant [usan]
5. Rad-1901
6. Er-306323
7. Fm6a2627a8
8. (6r)-6-[2-[ethyl-[[4-[2-(ethylamino)ethyl]phenyl]methyl]amino]-4-methoxyphenyl]-5,6,7,8-tetrahydronaphthalen-2-ol
9. (6r)-6-{2-[ethyl({4-[2-(ethylamino)ethyl]phenyl}methyl)amino]-4-methoxyphenyl}-5,6,7,8-tetrahydronaphthalen-2-ol
10. (2r)-2-(2-(ethyl-((4-(2-(ethylamino)ethyl)phenyl)methyl)amino)-4-methoxy-phenyl)tetralin-6-ol
11. (6r)-6-(2-(ethyl((4-(2- (ethylamino)ethyl)phenyl)methyl)amino)-4-methoxyphenyl)- 5,6,7,8-tetrahydronaphthalen-2-ol
12. 2-naphthalenol, 6-(2-(ethyl((4-(2-(ethylamino)ethyl)phenyl)methyl)amino)-4-methoxyphenyl)-5,6,7,8-tetrahydro-, (6r)-
13. Elacestrant (usan/inn)
14. Elacestrant [usan:inn]
15. Elacestrant [who-dd]
16. Schembl229431
17. Unii-fm6a2627a8
18. Chembl4297509
19. Bdbm349630
20. Dtxsid901045846
21. Glxc-26208
22. Ex-a5070
23. Us10208011, Compound Rad-
24. Mfcd30532693
25. Who 10247
26. Cs-6306
27. Db06374
28. Hy-19822
29. D11671
30. Q27278069
31. (r)-6-(2-(ethyl(4-(2-(ethylamino)ethyl)benzyl)amino)-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol
32. I0v
Molecular Weight | 458.6 g/mol |
---|---|
Molecular Formula | C30H38N2O2 |
XLogP3 | 6.3 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 10 |
Exact Mass | 458.293328459 g/mol |
Monoisotopic Mass | 458.293328459 g/mol |
Topological Polar Surface Area | 44.7 Ų |
Heavy Atom Count | 34 |
Formal Charge | 0 |
Complexity | 578 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in menopause and female hormonal deficiencies/abnormalities.
RAD1901 is a novel selective estrogen receptor modulator(SERM). SERMs are small molecules that bind to and selectively modulate estrogen receptors. These molecules have the ability to stimulate or block estrogen's activity in different types of tissue, functioning as estrogen receptor agonists in some tissues and as estrogen receptor antagonists in others. RAD1901 has potential to reduce vasomotor symptoms, along with a simultaneous bone-protective effect, without stimulating breast or uterine tissues. RAD1901 is distinctive from other SERMs in its unique biological profile, combined with its significant ability to penetrate the blood-brain barrier, which enables RAD1901 to function as an estrogen agonist within the central nervous system and thereby relieve hot flashes.
Market Place
ABOUT THIS PAGE
74
PharmaCompass offers a list of Elacestrant API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Elacestrant manufacturer or Elacestrant supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Elacestrant manufacturer or Elacestrant supplier.
PharmaCompass also assists you with knowing the Elacestrant API Price utilized in the formulation of products. Elacestrant API Price is not always fixed or binding as the Elacestrant Price is obtained through a variety of data sources. The Elacestrant Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Elacestrant manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Elacestrant, including repackagers and relabelers. The FDA regulates Elacestrant manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Elacestrant API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Elacestrant manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Elacestrant supplier is an individual or a company that provides Elacestrant active pharmaceutical ingredient (API) or Elacestrant finished formulations upon request. The Elacestrant suppliers may include Elacestrant API manufacturers, exporters, distributors and traders.
click here to find a list of Elacestrant suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Elacestrant Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Elacestrant GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Elacestrant GMP manufacturer or Elacestrant GMP API supplier for your needs.
A Elacestrant CoA (Certificate of Analysis) is a formal document that attests to Elacestrant's compliance with Elacestrant specifications and serves as a tool for batch-level quality control.
Elacestrant CoA mostly includes findings from lab analyses of a specific batch. For each Elacestrant CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Elacestrant may be tested according to a variety of international standards, such as European Pharmacopoeia (Elacestrant EP), Elacestrant JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Elacestrant USP).